Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia

類似資料

• Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
  著者:: Papanota, Aristea-Maria, 等
  出版事項: (2019)
• Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia
  著者:: Castillo, Jorge J., 等
  出版事項: (2018)
• Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia
  著者:: Raedler, Lisa A.
  出版事項: (2015)
• Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
  著者:: Papanota AM, 等
  出版事項: (2019-08-01)
• Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy
  著者:: Aiello, Andrea, 等
  出版事項: (2017)